Loading…
Loading…
Tempus AI (NASDAQ: TEM) executives said the company's planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities. On a call with analysts, Tempus said it agreed to acquire all outstanding shares of Personalis not already owned by Tempus at $16.25
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Personalis, Inc. (NasdaqGM: PSNL) to Tempus AI, Inc. (NasdaqGS: TEM). Under the terms of the proposed transaction, shareholders of Personalis will receive $16.25 per common share. The consideration is reported to be structured as a 100% stock transaction, with Tempus having the option to elect paymen.
On Monday, Tempus AI, Inc. (NASDAQ:TEM) agreed to acquire Personalis, Inc. (NASDAQ:PSNL), aiming to advance cancer monitoring through enhanced minimal residual disease (MRD) capabilities.
Amova Asset Management Americas Inc. raised its stake in Tempus AI, Inc. (NASDAQ: TEM) by 23.4% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 4,326,313 shares of the company's stock after purchasing an additional 821,490 shares during the quarter. Tempus AI accounts for 2.8% of
Tempus AI Inc. (NASDAQ:TEM) investors have a decision to make. Shares of the precision medicine company fell nearly 6% Monday, taking year-to-date losses to 16%, after it announced a $1.5 billion all-stock acquisition of Personalis, Inc. (NASDAQ:PSNL) — a deal that expands its oncology platform but also raises concerns about shareholder dilution ahead of earnings on July 30.
Tempus AI NASDAQ: TEM executives said the company's planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities.
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a nationally recognized shareholder rights firm, is investigating the proposed acquisition of Personalis, Inc. (Nasdaq: PSNL) by Tempus AI, Inc. (Nasdaq: TEM), an existing Personalis shareholder and strategic partner.
Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday. But shares of both medtech companies skidded.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for TEM and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.